Last updated: February 21, 2026
What is NDc 51407-0467?
NDc 51407-0467 is identified as a specific drug product in the National Drug Code (NDC) Directory. Based on available data, it is the Injectable Ziv-Aflibercept (Eylea) 2 mg/0.2 mL used for ocular conditions such as age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal vascular diseases.
Market Overview
Indications and Competitive Landscape
Ziv-Aflibercept, marketed as Eylea by Regeneron Pharmaceuticals, faces competition primarily from:
- Ranibizumab (Lucentis) by Genentech and Novartis
- Bevacizumab (Avastin) by Roche (off-label use in ocular indications)
- Emerging biosimilars, pending regulatory approval
Market Size and Demand
- The global ophthalmic anti-VEGF market was valued over $7 billion in 2022 and projected to exceed $12 billion by 2030 (Research and Markets, 2023).
- Specific to anti-VEGF agents for AMD, the U.S. market accounts for approximately $3.5 billion annually.
Key Drivers
- Aging population with increased AMD prevalence
- Growing adoption of intravitreal injections
- Patent expirations of major biologics and entry of biosimilars
Regulatory and Reimbursement Environment
- FDA-approved in 2011
- Reimbursement policies favor high-volume use
- Medicare covers anti-VEGF injections, influencing demand patterns
Price Projection Analysis
Pricing Data
Currently, the average wholesale price (AWP) per dose for Ziv-Aflibercept (NDc 51407-0467) is approximately $1,950 to $2,250 (Red Book, 2023). Actual transaction prices tend to be lower due to discounts and rebates.
| Price Metric |
Current Range |
Notes |
| Wholesale Acquisition Cost (WAC) |
$1,950 - $2,250 |
Retail drug pricing, before discounts |
| Average Sale Price (ASP) |
~$1,700 |
Reflects average negotiated prices |
| Reimbursement Rate (Medicare) |
~$1,800 |
Varies based on region and provider contracts |
Short-Term (Next 1-2 Years)
- No imminent patent expirations for the branded formulation.
- Limited biosimilar competition, expected minimal impact on price.
- Slight downward pressure expected from value-based pricing initiatives and tighter formulary controls.
Medium to Long-Term (3-5 Years)
- Patent cliff potentially occurring around 2025 for the branded product.
- Biosimilar entry anticipated between 2024-2026, which could decrease prices by 20-40%.
- Price reductions likely driven by increased biosimilar market penetration.
Price Projections Summary
| Year |
Projected WAC |
Projected ASP |
Notes |
| 2023 |
$2,000 |
$1,700 |
Current prices stable |
| 2024 |
$1,950 |
$1,650 |
Biosimilar entries begin, slight discounting |
| 2025 |
$1,850 |
$1,500 |
Biosimilar market expansion, more competition |
| 2026 |
$1,750 |
$1,400 |
Increased biosimilar adoption, price competition |
Key Market Risks
- Accelerated biosimilar approvals and launches could suppress prices sooner.
- Changes in reimbursement policies, especially in the US, could influence pricing strategies.
- Patent litigation or delays in biosimilar market entry.
Conclusion
The drug associated with NDC 51407-0467 currently commands a retail price ranging from $1,700 to $2,250 per dose. The next 1-2 years will likely see continued price stability, with minor reductions driven by market negotiations. Long-term projections suggest a possible 15-25% decrease as biosimilars enter and capture market share starting around 2024.
Key Takeaways
- The current market for NDc 51407-0467 is valued at nearly $1.7 billion annually in the U.S. for ocular indications.
- The drug's price is expected to adjust downward by 20-30% over the next five years due to biosimilar competition.
- Growth drivers include aging demographics and increased adoption of anti-VEGF therapies.
- Regulatory and reimbursement policies significantly influence market dynamics.
- Price reductions will be incremental unless accelerated biosimilar approvals occur.
FAQs
1. When will biosimilars for NDc 51407-0467 become widely available?
Biosimilar applications are expected around 2024-2026, with market entry potentially occurring within 1-2 years after approval, depending on regulatory and patent considerations.
2. How much could biosimilar competition reduce the price of NDc 51407-0467?
Biosimilars could cut prices by 20-40%, depending on market uptake and formulary preferences.
3. What are the primary reimbursement considerations for this drug?
Centers for Medicare & Medicaid Services (CMS) covers anti-VEGF injections with reimbursement rates typically aligned with ASPs, influencing net revenue for providers.
4. Are there any upcoming patent expirations for the branded product?
Pending patent reviews, expiration is estimated around 2025-2026, which align with biosimilar market introductions.
5. How does regional variation affect the drug's pricing?
Pricing varies by payer, region, and negotiated discounts. U.S. prices tend to be higher than international markets due to different reimbursement and pricing regulations.
References
- Research and Markets. (2023). Global ophthalmic anti-VEGF drugs market size, share, growth, and forecast.
- Red Book. (2023). Average wholesale prices for ophthalmic biologics.
- U.S. Food and Drug Administration. (2011). Approval details for Ziv-Aflibercept.
- CMS.gov. (2023). Medicare reimbursement policies for ophthalmic injections.
[1] Regeneron Pharmaceuticals Inc. (2022). Eylea (Ziv-Aflibercept) Prescribing Information.
